Pharmaceutical industry
Genentech and Biogen Idec have been working together to bring Rituxan, a therapeutic antibody, to the market as a treatment for chronic lymphocytic leukemia (CLL). The U.S. Food and Drug Administration (FDA) has issued a complete response on the companies' applications for Rituxan plus fludarabine and cyclophosphamide (FC)
Pharmaceutical industry
Psychiatric Solutions, Inc. (PSI) has launched PSI Patriot Support, an expanded program to provide behavioral health services to military members and their families at PSI facilities across the country. This initiative reflects PSI's commitment to addressing the stress and trauma associated with war. In conjunction with this announcement,
Pharmaceutical industry
Representatives from key US and international agencies, policy makers, major pharmaceutical companies, and biotechnology were in attendance at Influenza Congress USA 2009, a national symposium held in Washington, D.C. last week. Dr. Douglas Powell, Director of Immunobiology at Antigen Express, Inc., a wholly-owned immunotherapeutics subsidiary of Generex, presented the
Pharmaceutical industry
Human Genome Sciences, Inc. (HGS) and GlaxoSmithKline PLC (GSK) have announced that BENLYSTA™ (belimumab) has met the primary endpoint in the BLISS-76 trial, a pivotal Phase 3 study in seropositive patients with systemic lupus erythematosus (SLE). The study results through 52 weeks showed that belimumab 10 mg/kg plus standard
Pharmaceutical industry
In a rare instance, email exchanges between Washington lobbyists and lawmakers have revealed a coordinated effort to influence the Congressional Record. The communications, obtained by The New York Times, show that lobbyists working for Genentech, a Swiss drug giant, drafted statements for lawmakers to submit to the Congressional Record. These
Pharmaceutical industry
Lonza Group, Ltd., a Switzerland-based supplier of pharmaceutical active ingredients, has signed a significant agreement with GlaxoSmithKline plc (GSK) and Genmab A/S for the manufacturing of Arzerra, a monoclonal antibody approved by the US Food and Drug Administration (FDA) for treating chronic lymphocytic leukemia (CLL). Under the agreement, Lonza
Pharmaceutical industry
Preclinical studies conducted by Halsa Pharmaceuticals, Inc. have demonstrated the potential therapeutic benefits of recombinant human Zinc-a2-glycoprotein (ZAG) in treating obesity and Type 2 diabetes. The studies showed that ZAG induced a significant loss of body weight in mice, normalized diabetic glucose tolerance curves, and exhibited low acute toxicity. These
Pharmaceutical industry
FinancialWire, a proprietary news wire service, provided the conference call schedule for November 3, 2009. The schedule included calls from various companies such as F5 Networks Inc., Cognizant Technology Solutions, and Crucell N.V. ADR, among others. These calls were made available through the Conference Call Search Function on the
Pharmaceutical industry
In a significant breakthrough for the treatment of systemic lupus erythematosus (SLE), Human Genome Sciences, Inc. (HGS) and GlaxoSmithKline PLC (GSK) announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with SLE. The data, presented at the
Pharmaceutical industry
Halsa Pharmaceuticals, a biotechnology company, has announced results from preclinical studies demonstrating the potential of recombinant human Zinc-2-glycoprotein (ZAG) in treating obesity and Type 2 diabetes. The studies showed that ZAG induced a progressive loss of body weight in mice, along with an increase in temperature and metabolic hallmarks of
Pharmaceutical industry
Dr. John Rothman, Executive Vice President of Science and Operations at Advaxis, Inc., will be presenting at GTCbio's Fifth Annual Modern Drug Discovery & Development Summit in San Diego, CA on October 16, 2009. The conference brings together leading biotechnology and pharmaceutical companies, including F. Hoffmann-La Roche Ltd.
Pharmaceutical industry
BioMedReports.com, a news portal covering the biomedical sector, has updated its calendar database of clinical trials and upcoming FDA approvals and decisions for biotech investors. The database now includes detailed information on various biopharmaceutical companies, including Seattle Genetics, Inc. (Nasdaq:SGEN) and Dynavax Technologies Corporation (Nasdaq:DVAX), which recently
